Al-Kaabi A. Baranov N.S. van der Post R.S. et al.

Age-specific incidence, treatment, and survival trends in esophageal cancer: a Dutch population-based cohort study.

Acta Oncol. : 1-8Coupland V.H. Allum W. Blazeby J.M. et al.

Incidence and survival of oesophageal and gastric cancer in England between 1998 and 2007, a population-based study.

BMC Cancer. 12: 11Dubecz A. Solymosi N. Stadlhuber R.J. et al.

Does the Incidence of Adenocarcinoma of the Esophagus and Gastric Cardia Continue to Rise in the Twenty-First Century?-a SEER Database Analysis.

J Gastrointest Surg. 18: 124-129Bray F. Ferlay J. Soerjomataram I. et al.

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

CA Cancer J Clin. 68: 394-424

The global, regional, and national burden of stomach cancer in 195 countries, 1990-2017: a systematic analysis for the Global Burden of Disease study 2017.

Lancet Gastroenterol Hepatol. 5: 42-54Siewert J.R. Holscher A.H. Becker K. et al.

[Cardia cancer: attempt at a therapeutically relevant classification].

Chirurg. 58: 25-32Rice T.W. Rusch V.W. Apperson-Hansen C. et al.

Worldwide esophageal cancer collaboration.

Dis Esophagus. 22: 1-8AJCC cancer staging Manual, TNM classification of malignant tumours. 7th Edition. Springer-Verlag, New York

TNM classification of malignant tumours, 8th Edition. Wiley-Blackwell 2016. James D. Brierley CW, editor: Wiley-Blackwell; 2016.

Haverkamp L. Seesing M.F. Ruurda J.P. et al.

Worldwide trends in surgical techniques in the treatment of esophageal and gastroesophageal junction cancer.

Dis Esophagus. 30: 1-7Delattre J.-F. Avisse C. Marcus C. et al.

Functional Anatomy of the Gastroesophageal Junction.

Surg Clin North Am. 80: 241-260Greenson J.K.L.G. Owens S.R. Montgomery E.A.

Diagnostic pathology: Gastrointestinal.

2nd edition. Elsevier,

Adenocarcinoma of the gastroesophageal junction: classifcation, pathology and extent of resection.

Dis Esophagus. 9: 173-182Rudiger Siewert J. Feith M. Werner M. et al.

Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients.

Ann Surg. 232: 353-361Stein H.J. Feith M. Siewert J.R.

Cancer of the esophagogastric junction.

Surg Oncol. 9: 35-41Cameron A.J.L.C. Pera M. Carpenter H.A.

Adenocarcinoma of the esophagogastric junction and Barrett's esophagus.

Gastroenterology. 109: 1541-1546Chalasani N. Wo J.M. Hunter J.G. et al.

Significance of intestinal metaplasia in different areas of esophagus including esophagogastric junction.

Dig Dis Sci. 42: 603-607

Classification of adenocarcinoma of the oesophagogastric junction.

Br J Surg. 85: 1457-1459Sitarz R. Skierucha M. Mielko J. et al.

Gastric cancer: epidemiology, prevention, classification, and treatment.

Cancer Manag Res. 10: 239-248Etemadi A. Safiri S. Sepanlou S.G. et al.

The global, regional, and national burden of stomach cancer in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease study 2017.

Lancet Gastroenterol Hepatol. 5: 42-54van Dekken H.G.E. Dinjens W.N. Winjnhoven B.P. et al.

Comparative genomic hybridization of cancer of the gastroesophageal junction: deletion of 14Q31-32.1 discriminates between esophageal (Barrett's) and gastric cardia adenocarcinomas.

Cancer Res. 59: 748-752van Dekken H. Alers J.C. Riegman P.H.J. et al.

Molecular Cytogenetic Evaluation of Gastric Cardia Adenocarcinoma and Precursor Lesions.

Am J Pathol. 158: 1961-1967Codipilly D.C. Chandar A.K. Singh S. et al.

The Effect of Endoscopic Surveillance in Patients With Barrett's Esophagus: A Systematic Review and Meta-analysis.

Gastroenterology. 154: 2068-20686 e5Hvid-Jensen F. Pedersen L. Drewes A.M. et al.

Incidence of adenocarcinoma among patients with Barrett's esophagus.

N Engl J Med. 365: 1375-1383Corley D.A. Mehtani K. Quesenberry C. et al.

Impact of endoscopic surveillance on mortality from Barrett's esophagus-associated esophageal adenocarcinomas.

Gastroenterology. 145: 312-319 e1Reid B.J. Li X. Galipeau P.C. et al.

Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis.

Nat Rev Cancer. 10: 87-101Romagnuolo J.S.J. Hawes R.H. Hoffman B.J. et al.

Helical CT versus EUS with fine needle aspiration for celiac nodal assessment in patients with esophageal cancer.

Gastrointest Endosc. 55: 648-654Dubecz A. Kern M. Solymosi N. et al.

Predictors of Lymph Node Metastasis in Surgically Resected T1 Esophageal Cancer.

Ann Thorac Surg. 99 (): 1879-1885Pouw R.E. Heldoorn N. Alvarez Herrero L. et al.

Do we still need EUS in the workup of patients with early esophageal neoplasia? A retrospective analysis of 131 cases.

Gastrointest Endosc. 73: 662-668Dhupar R. Rice R.D. Correa A.M. et al.

Endoscopic Ultrasound Estimates for Tumor Depth at the Gastroesophageal Junction Are Inaccurate: Implications for the Liberal Use of Endoscopic Resection.

Ann Thorac Surg. 100: 1812-1816Yang G.Y.W.T. Jobe B.A. Thomas C.R.

The role of positron emission tomography in esophageal cancer.

Gastrointest Cancer Res. 1: 3-9Flamen P. Lerut A. Van Cutsem E. et al.

Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma.

J Clin Oncol. 18: 3202-3210Cuellar S.L. Carter B.W. Macapinlac H.A. et al.

Clinical staging of patients with early esophageal adenocarcinoma: does FDG-PET/CT have a role?.

J Thorac Oncol. 9: 1202-1206Sasako M. Sano T. Yamamoto S. et al.

Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial.

Lancet Oncol. 7: 644-651Kurokawa Y. Sasako M. Sano T. et al.

Ten-year follow-up results of a randomized clinical trial comparing left thoracoabdominal and abdominal transhiatal approaches to total gastrectomy for adenocarcinoma of the oesophagogastric junction or gastric cardia.

Br J Surg. 102: 341-348Hulscher J.B. van Sandick J.W. de Boer A.G. et al.

Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus.

N Engl J Med. 347: 1662-1669Omloo J.M. Lagarde S.M. Hulscher J.B. et al.

Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial.

Ann Surg. 246 (): 992-1000Blank S. Schmidt T. Heger P. et al.

Surgical strategies in true adenocarcinoma of the esophagogastric junction (AEG II): thoracoabdominal or abdominal approach?.

Gastric Cancer. 21: 303-314Kamarajah S.K. Markar S.R.

Esophagectomy or Total Gastrectomy for Siewert 2 Gastroesophageal Junction (GEJ) Adenocarcinoma: An Ongoing Debate.

Ann Surg Oncol. 29: 750Anderegg M.C. Lagarde S.M. Jagadesham V.P. et al.

Prognostic Significance of the Location of Lymph Node Metastases in Patients With Adenocarcinoma of the Distal Esophagus or Gastroesophageal Junction.

Ann Surg. 264: 847-853Phillips A.W. Lagarde S.M. Navidi M. et al.

Impact of Extent of Lymphadenectomy on Survival, Post Neoadjuvant Chemotherapy and Transthoracic Esophagectomy.

Ann Surg. 265: 750-756Mertens A.C. Kalff M.C. Eshuis W.J. et al.

Transthoracic Versus Transhiatal Esophagectomy for Esophageal Cancer: A Nationwide Propensity Score-Matched Cohort Analysis.

Ann Surg Oncol. 28: 175-183Colvin H. Dunning J. Khan O.A.

Transthoracic versus transhiatal esophagectomy for distal esophageal cancer: which is superior?.

Interact Cardiovasc Thorac Surg. 12: 265-269Barbour A.P. Rizk N.P. Gonen M. et al.

Adenocarcinoma of the gastroesophageal junction: influence of esophageal resection margin and operative approach on outcome.

Ann Surg. 246: 1-8Biere S.S. van Berge Henegouwen M.I. Maas K.W. et al.

Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial.

Lancet. 379: 1887-1892van der Sluis P.C. van der Horst S. May A.M. et al.

Robot-assisted Minimally Invasive Thoracolaparoscopic Esophagectomy Versus Open Transthoracic Esophagectomy for Resectable Esophageal Cancer: A Randomized Controlled Trial.

Ann Surg. 269: 621-630Mariette C. Markar S.R. Dabakuyo-Yonli T.S. et al.

Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer.

N Engl J Med. 380: 152-162Aaronson N.K. Ahmedzai S. Bergman B. et al.

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.

J Natl Cancer Inst. 85: 365-376Blazeby J.M. Alderson D. Winstone K. et al.

Development of an EORTC questionnaire module to be used in quality of life assessment for patients with oesophageal cancer.

Eur J Cancer. 32: 1912-1917van der Schaaf M. Derogar M. Lagergren P.

Reference values of oesophago-gastric symptoms (EORTC QLQ-OG25) in a population-based setting.

Eur J Cancer. 48: 1602-1607Barbour A.P. Lagergren P. Hughes R. et al.

Health-related quality of life among patients with adenocarcinoma of the gastro-oesophageal junction treated by gastrectomy or oesophagectomy.

Br J Surg. 95: 80-84Jezerskyte E. Saadeh L.M. Hagens E.R.C. et al.

Long-Term Quality of Life After Total Gastrectomy Versus Ivor Lewis Esophagectomy.

World J Surg. 44: 838-848Fuchs H. Holscher A.H. Leers J. et al.

Long-term quality of life after surgery for adenocarcinoma of the esophagogastric junction: extended gastrectomy or transthoracic esophagectomy?.

Gastric Cancer. 19: 312-317Mitchell K.G. Ikoma N. Nelson D.B. et al.

Mediastinal Nodal Involvement After Neoadjuvant Chemoradiation for Siewert II/III Adenocarcinoma.

Ann Thorac Surg. 108: 845-851Mine S. Sano T. Hiki N. et al.

Proximal margin length with transhiatal gastrectomy for Siewert type II and III adenocarcinomas of the oesophagogastric junction.

Br J Surg. 100: 1050-1054van Hagen P. Hulshof M.C. van Lanschot J.J. et al.

Preoperative chemoradiotherapy for esophageal or junctional cancer.

N Engl J Med. 366: 2074-2084Shapiro J. van Lanschot JJB Hulshof M.C.C.M. et al.

Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.

Lancet Oncol. 16: 1090-1098Cunningham D. Allum W.H. Stenning S.P. et al.

Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.

N Engl J Med. 355: 11-20Al-Batran S.-E. Homann N. Pauligk C. et al.

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.

Lancet. 393: 1948-1957Reynolds J.V. Preston S.R. O'Neill B. et al.

Neo-AEGIS (Neoadjuvant trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction International Study): Preliminary results of phase III RCT of CROSS versus perioperative chemotherapy (Modified MAGIC or FLOT protocol). (NCT01726452).

J Clin Oncol. 39: 4004Hoeppner J. Lordick F. Brunner T. et al.

ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286).

BMC Cancer. 16: 503Al-Batran S.E. Homann N. Pauligk C. et al.

Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.

JAMA Oncol. 3: 1237-1244Kelly R.J. Ajani J.A. Kuzdzal J. et al.

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.

N Engl J Med. 384: 1191-1203Puhr H.C. Preusser M. Ilhan-Mutlu A.

Immunotherapy for Esophageal Cancers: What Is Practice Changing in 2021?.

Cancers (Basel). 13Kamarajah S.K. Phillips A.W. Griffiths E.A. et al.

Esophagectomy or Total Gastrectomy for Siewert 2 Gastroesophageal Junction (GEJ) Adenocarcinoma? A Registry-Based Analysis.

Ann Surg Oncol. 28: 8485-8494Haverkamp L. Ruurda J.P. van Leeuwen M.S. et al.

Systematic review of the surgical strategies of adenocarcinomas of the gastroesophageal junction.

Surg Oncol. 23: 222-228